Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Posted: August 5, 2022 at 2:03 am

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics

Read more from the original source:
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Related Posts